GlobeNewswire
-
Serotonin Anti-Aging Centers Founder Puts a Physician-Led Longevity Clinic Inside New York Sports Club
12/11/2026 -
HerScan CEO CiCi McMullen Featured in Forbes for Leadership in Expanding Breast Health Screenings
12/11/2026 -
DBV Technologies présente de nouvelles données issues de l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans
12/11/2026 -
DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
12/11/2026 -
Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy
12/11/2026 -
Resilio Mental Health Solutions Celebrates New Exton Office with Chamber Ribbon Cutting
12/11/2026 -
Jersey College to Graduate First Nursing Class From Its Dothan, Alabama, Campus
12/11/2026 -
New Study Links Fitness Engagement to Lower Medicare Inpatient Costs
12/11/2026 -
CCP Now Lansdale Brings Specialized Walk-In Cardiac Care to Montgomery County
12/11/2026 -
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
12/11/2026 -
ALK to present positive phase II data on its tablet for the treatment of peanut allergy at ACAAI 2026
12/11/2026 -
NYC Mommy Makeover Center Supports Local Moms as Mommy Makeover Interest Jumps 60%
12/11/2026 -
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
12/11/2026 -
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
12/11/2026 -
Patients Know Best Launches in Australia through Consultmed partnership
12/11/2026 -
Ally Medical ER Named a 2026 Top Workplace by Houston Chronicle, Earns Best Manager Award
12/11/2026 -
Lungpacer Medical Announces First Patient Enrollment in AERO-PAS Post-Approval Study of the AeroPace® System
12/11/2026 -
QUAD A Announces Dr. Monte Jay Goldstein as President of Its Board of Directors
12/11/2026 -
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
12/11/2026
Pages